Today, Illumina Inc. (ILMN) Stake Boosted by Sentry Investment Management LLC

Today, Illumina Inc. (ILMN) Stake Boosted by Sentry Investment Management LLC
Sentry Investment Management LLC increased its stake in Illumina Inc. (NASDAQ:ILMN) by 3.6% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 10,649 shares of the life sciences company’s stock after buying an additional 368 shares during the period. Sentry Investment Management LLC’s holdings in Illumina were worth $1,934,000 at the end of the most recent quarter.

A number of other large investors also recently modified their holdings of the company. Physicians Financial Services Inc. raised its stake in Illumina by 2,121.2% in the second quarter. Physicians Financial Services Inc. now owns 733 shares of the life sciences company’s stock worth $103,000 after buying an additional 700 shares during the last quarter. Global X Management Co. LLC raised its stake in Illumina by 1,400.0% in the third quarter. Global X Management Co. LLC now owns 600 shares of the life sciences company’s stock worth $109,000 after buying an additional 560 shares during the last quarter. Northwestern Mutual Wealth Management Co. raised its stake in Illumina by 25.0% in the second quarter. Northwestern Mutual Wealth Management Co. now owns 789 shares of the life sciences company’s stock worth $110,000 after buying an additional 158 shares during the last quarter. Fuller & Thaler Asset Management Inc. acquired a new stake in Illumina during the second quarter worth about $112,000. Finally, Ropes Wealth Advisors LLC raised its stake in Illumina by 72.6% in the second quarter. Ropes Wealth Advisors LLC now owns 863 shares of the life sciences company’s stock worth $121,000 after buying an additional 363 shares during the last quarter. 93.52% of the stock is owned by institutional investors.

Shares of Illumina Inc. (NASDAQ:ILMN) opened at 134.43 on Friday. The firm has a market capitalization of $19.75 billion, a P/E ratio of 45.11 and a beta of 1.24. Illumina Inc. has a 12-month low of $127.10 and a 12-month high of $196.47. The stock has a 50 day moving average price of $143.11 and a 200 day moving average price of $152.84.

Illumina (NASDAQ:ILMN) last released its quarterly earnings results on Tuesday, November 1st. The life sciences company reported $0.97 EPS for the quarter, topping the consensus estimate of $0.87 by $0.10. The firm had revenue of $607 million for the quarter, compared to analyst estimates of $628.06 million. Illumina had a return on equity of 23.76% and a net margin of 18.72%. Illumina’s revenue for the quarter was up 10.4% on a year-over-year basis. During the same period in the previous year, the company posted $0.80 EPS. Equities analysts anticipate that Illumina Inc. will post $3.32 earnings per share for the current fiscal year.

ILMN has been the subject of a number of research reports. Vetr raised shares of Illumina from a “sell” rating to a “buy” rating and set a $198.61 target price for the company in a report on Monday, October 3rd. Citigroup Inc. boosted their price target on shares of Illumina from $175.00 to $190.00 and gave the company a “buy” rating in a research report on Monday, September 12th. Zacks Investment Research raised shares of Illumina from a “hold” rating to a “buy” rating and set a $190.00 price target on the stock in a research report on Friday, August 26th. Argus boosted their price target on shares of Illumina from $175.00 to $185.00 and gave the company a “buy” rating in a research report on Monday, August 8th. Finally, Barclays PLC set a $142.00 price target on shares of Illumina and gave the company an “equal weight” rating in a research report on Tuesday, October 11th. Four analysts have rated the stock with a sell rating, fifteen have given a hold rating and seven have given a buy rating to the company’s stock. The stock has an average rating of “Hold” and an average price target of $152.88.

In other Illumina news, EVP Marc Stapley sold 1,270 shares of Illumina stock in a transaction that occurred on Thursday, September 15th. The stock was sold at an average price of $172.87, for a total transaction of $219,544.90. Following the sale, the executive vice president now directly owns 33,916 shares in the company, valued at approximately $5,863,058.92. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Daniel Bradbury sold 600 shares of Illumina stock in a transaction that occurred on Monday, November 14th. The stock was sold at an average price of $136.34, for a total value of $81,804.00. Following the sale, the director now owns 17,065 shares in the company, valued at $2,326,642.10. The disclosure for this sale can be found here. Corporate insiders own 1.60% of the company’s stock.

Illumina Company Profile

Illumina, Inc (Illumina) offers sequencing and array-based solutions for genetic analysis. The Company’s products and services serve customers in a range of markets, enabling the adoption of genomic solutions in research and clinical settings. The Company’s customers include genomic research centers, academic institutions, government laboratories and hospitals, as well as pharmaceutical, biotechnology, agrigenomics and commercial molecular diagnostic laboratories, and consumer genomics companies.

Related posts

Leave a Comment